# HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes

> **NCT04396626** · — · TERMINATED · sponsor: **Pfizer** · enrollment: 975 (actual)

## Conditions studied

- Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04396626
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-18
- **Primary completion:** 2020-05-31
- **Final completion:** 2020-05-31
- **Target enrollment:** 975 (ACTUAL)
- **Why stopped:** The study was prematurely discontinued due to significant data quality issues on August 26, 2021. There were no safety concerns that led to the decision to terminate.
- **Last updated:** 2023-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04396626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04396626, "HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04396626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*